Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce
pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF). In addition,
NP-120 significantly reduced both cough frequency and onset in a guinea pig tussive model.
The purpose of this proof-of-concept trial is to determine the efficacy of NP-120 in the
treatment of IPF and its associated cough.